BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35904492)

  • 1. Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation.
    Chen S; Vedula RS; Cuevas-Navarro A; Lu B; Hogg SJ; Wang E; Benbarche S; Knorr K; Kim WJ; Stanley RF; Cho H; Erickson C; Singer M; Cui D; Tittley S; Durham BH; Pavletich TS; Fiala E; Walsh MF; Inoue D; Monette S; Taylor J; Rosen N; McCormick F; Lindsley RC; Castel P; Abdel-Wahab O
    Cancer Discov; 2022 Oct; 12(10):2434-2453. PubMed ID: 35904492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LZTR1 facilitates polyubiquitination and degradation of RAS-GTPases.
    Abe T; Umeki I; Kanno SI; Inoue SI; Niihori T; Aoki Y
    Cell Death Differ; 2020 Mar; 27(3):1023-1035. PubMed ID: 31337872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RIT1 oncoproteins escape LZTR1-mediated proteolysis.
    Castel P; Cheng A; Cuevas-Navarro A; Everman DB; Papageorge AG; Simanshu DK; Tankka A; Galeas J; Urisman A; McCormick F
    Science; 2019 Mar; 363(6432):1226-1230. PubMed ID: 30872527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-species analysis of LZTR1 loss-of-function mutants demonstrates dependency to RIT1 orthologs.
    Cuevas-Navarro A; Rodriguez-Muñoz L; Grego-Bessa J; Cheng A; Rauen KA; Urisman A; McCormick F; Jimenez G; Castel P
    Elife; 2022 Apr; 11():. PubMed ID: 35467524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LZTR1 is a regulator of RAS ubiquitination and signaling.
    Bigenzahn JW; Collu GM; Kartnig F; Pieraks M; Vladimer GI; Heinz LX; Sedlyarov V; Schischlik F; Fauster A; Rebsamen M; Parapatics K; Blomen VA; Müller AC; Winter GE; Kralovics R; Brummelkamp TR; Mlodzik M; Superti-Furga G
    Science; 2018 Dec; 362(6419):1171-1177. PubMed ID: 30442766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination.
    Steklov M; Pandolfi S; Baietti MF; Batiuk A; Carai P; Najm P; Zhang M; Jang H; Renzi F; Cai Y; Abbasi Asbagh L; Pastor T; De Troyer M; Simicek M; Radaelli E; Brems H; Legius E; Tavernier J; Gevaert K; Impens F; Messiaen L; Nussinov R; Heymans S; Eyckerman S; Sablina AA
    Science; 2018 Dec; 362(6419):1177-1182. PubMed ID: 30442762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Model for Recruitment of RIT1 to the LZTR1 E3 Ligase: Evidences from an Integrated Computational Approach.
    Paladino A; D'Angelo F; Noviello TMR; Iavarone A; Ceccarelli M
    J Chem Inf Model; 2021 Apr; 61(4):1875-1888. PubMed ID: 33792302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GSK3 kinase and LZTR1 protein regulate the stability of Ras family proteins and the proliferation of pancreatic cancer cells.
    Palanivel C; Chaudhary N; Seshacharyulu P; Cox JL; Yan Y; Batra SK; Ouellette MM
    Neoplasia; 2022 Mar; 25():28-40. PubMed ID: 35114566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex.
    Damianou A; Liang Z; Lassen F; Vendrell I; Vere G; Hester S; Charles PD; Pinto-Fernandez A; Santos A; Fischer R; Kessler BM
    Life Sci Alliance; 2024 May; 7(5):. PubMed ID: 38453365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling.
    Motta M; Fidan M; Bellacchio E; Pantaleoni F; Schneider-Heieck K; Coppola S; Borck G; Salviati L; Zenker M; Cirstea IC; Tartaglia M
    Hum Mol Genet; 2019 Mar; 28(6):1007-1022. PubMed ID: 30481304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical Classification of Disease-associated Mutants of RAS-like Protein Expressed in Many Tissues (RIT1).
    Fang Z; Marshall CB; Yin JC; Mazhab-Jafari MT; Gasmi-Seabrook GM; Smith MJ; Nishikawa T; Xu Y; Neel BG; Ikura M
    J Biol Chem; 2016 Jul; 291(30):15641-52. PubMed ID: 27226556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LZTR1 deficiency exerts high metastatic potential by enhancing sensitivity to EMT induction and controlling KLHL12-mediated collagen secretion.
    Abe T; Kanno SI; Niihori T; Terao M; Takada S; Aoki Y
    Cell Death Dis; 2023 Aug; 14(8):556. PubMed ID: 37626065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Degradation of activated K-Ras orthologue via K-Ras-specific lysine residues is required for cytokinesis.
    Sumita K; Yoshino H; Sasaki M; Majd N; Kahoud ER; Takahashi H; Takeuchi K; Kuroda T; Lee S; Charest PG; Takeda K; Asara JM; Firtel RA; Anastasiou D; Sasaki AT
    J Biol Chem; 2014 Feb; 289(7):3950-9. PubMed ID: 24338482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.
    Mandanas RA; Leibowitz DS; Gharehbaghi K; Tauchi T; Burgess GS; Miyazawa K; Jayaram HN; Boswell HS
    Blood; 1993 Sep; 82(6):1838-47. PubMed ID: 7691239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
    McMahon CM; Ferng T; Canaani J; Wang ES; Morrissette JJD; Eastburn DJ; Pellegrino M; Durruthy-Durruthy R; Watt CD; Asthana S; Lasater EA; DeFilippis R; Peretz CAC; McGary LHF; Deihimi S; Logan AC; Luger SM; Shah NP; Carroll M; Smith CC; Perl AE
    Cancer Discov; 2019 Aug; 9(8):1050-1063. PubMed ID: 31088841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
    Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
    Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
    Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors.
    Yen I; Shanahan F; Merchant M; Orr C; Hunsaker T; Durk M; La H; Zhang X; Martin SE; Lin E; Chan J; Yu Y; Amin D; Neve RM; Gustafson A; Venkatanarayan A; Foster SA; Rudolph J; Klijn C; Malek S
    Cancer Cell; 2018 Oct; 34(4):611-625.e7. PubMed ID: 30300582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LZTR1: A promising adaptor of the CUL3 family.
    Zhang H; Cao X; Wang J; Li Q; Zhao Y; Jin X
    Oncol Lett; 2021 Jul; 22(1):564. PubMed ID: 34113392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition.
    Inoue D; Polaski JT; Taylor J; Castel P; Chen S; Kobayashi S; Hogg SJ; Hayashi Y; Pineda JMB; El Marabti E; Erickson C; Knorr K; Fukumoto M; Yamazaki H; Tanaka A; Fukui C; Lu SX; Durham BH; Liu B; Wang E; Mehta S; Zakheim D; Garippa R; Penson A; Chew GL; McCormick F; Bradley RK; Abdel-Wahab O
    Nat Genet; 2021 May; 53(5):707-718. PubMed ID: 33846634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.